Editas Medicine is a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Their goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer. 

Biotechnology

Editas Medicine

Gilmore O’Neill

Erick J. Lucera

Greg Whitehead

Baisong Mei

Caren Deardorf

Linda C. Burkly

Linea Aspesi

Charlene Stern

Chi Li

The board of directors at Editas Medicine have a wealth of experience in the healthcare and pharmaceutical industries. The founder of HG III Consulting, SVP Quality and Continuous Improvement at Patheon, Site Leader at Pfizer, and Director of Engineering at Baxter have all served on the board at some point. In addition, the board members have also attended East Tennessee State University, where they studied Microbiology.

Board of Directors

CEO and Executive Team

Leadership Team

Board of Directors

About

Team members

Other teams at Editas Medicine

CEO and Executive Team

Leadership Team